Impact of Overweight on Cancer Risk May Be Significantly Underestimated

Impact of Overweight on Cancer Risk May Be Significantly Underestimated

BioM, bioRN and ESMT Berlin join forces to create a Unified Hub for healthcare innovation in Germany

BioM, bioRN and ESMT Berlin join forces to create a Unified Hub for healthcare innovation in Germany

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VectorBuilder Advances Free VectorBee Software to Help Researchers Work with Greater Control and Flexibility

VectorBuilder Advances Free VectorBee Software to Help Researchers Work with Greater Control and Flexibility

Beyond Cell Painting: From Phenotypic Screening To Mechanistic Understanding Using Antibody Panels

Beyond Cell Painting: From Phenotypic Screening To Mechanistic Understanding Using Antibody Panels

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately